ARS Pharmaceuticals, Inc. Capital Expenditures Incurred but Not yet Paid
ARS Pharmaceuticals, Inc. (SPRY) reported Capital Expenditures Incurred but Not yet Paid of $0 for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-10.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2025-11-10
- ARS Pharmaceuticals, Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-09-30 was -$5.86M, a 6835.63% decline year-over-year.
- ARS Pharmaceuticals, Inc. capital expenditures incurred but not yet paid for the quarter ending 2024-09-30 was $87.00K.
- ARS Pharmaceuticals, Inc. capital expenditures incurred but not yet paid for the quarter ending 2024-06-30 was $0.00.
- ARS Pharmaceuticals, Inc. capital expenditures incurred but not yet paid for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- ARS Pharmaceuticals, Inc. capital expenditures incurred but not yet paid for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- ARS Pharmaceuticals, Inc. capital expenditures incurred but not yet paid for fiscal 2022 was $91.00K.
- ARS Pharmaceuticals, Inc. capital expenditures incurred but not yet paid for fiscal 2021 was $0.00.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 3 month as first filed | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|---|
| 2025-09-30 | -$5.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $0.00 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | $5.86M 10-Q · filed 2025-08-13 | ||||
| 2024-09-30 | $87.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $87.00K derived: sum of 2 quarters · filed 2025-11-10 | $87.00K 10-Q · filed 2025-11-10 | -$4.00K derived: sum of 4 quarters · filed 2025-11-10 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $0.00 10-Q · filed 2025-08-13 | -$91.00K derived: sum of 3 quarters · filed 2025-08-13 | -$91.00K derived: sum of 4 quarters · filed 2025-08-13 | |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-09 | -$91.00K derived: sum of 2 quarters · filed 2024-05-09 | -$91.00K derived: sum of 3 quarters · filed 2024-11-13 | -$91.00K derived: sum of 4 quarters · filed 2024-11-13 | |
| 2023-12-31 | -$91.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | -$91.00K derived: sum of 2 quarters · filed 2024-11-13 | -$91.00K derived: sum of 3 quarters · filed 2024-11-13 | $0.00 10-K · filed 2024-03-21 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $0.00 derived: sum of 2 quarters · filed 2024-11-13 | $91.00K 10-Q · filed 2024-11-13 | $182.00K derived: sum of 4 quarters · filed 2024-11-13 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $91.00K 10-Q · filed 2024-08-06 | $182.00K derived: sum of 3 quarters · filed 2024-08-06 | $182.00K derived: sum of 4 quarters · filed 2024-08-06 | |
| 2023-03-31 | $91.00K 10-Q · filed 2024-05-09 | $182.00K derived: sum of 2 quarters · filed 2024-05-09 | $182.00K derived: sum of 3 quarters · filed 2024-05-09 | $161.00K derived: sum of 4 quarters · filed 2024-05-09 | |
| 2022-12-31 | $91.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $91.00K derived: sum of 2 quarters · filed 2024-03-21 | $70.00K derived: sum of 3 quarters · filed 2024-03-21 | $91.00K 10-K · filed 2024-03-21 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$21.00K derived: sum of 2 quarters · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | -$21.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $0.00 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | $21.00K 10-Q · filed 2023-05-15 | $66.00K 10-Q · filed 2022-05-12 | |||
| 2021-12-31 | $0.00 10-K · filed 2023-03-23 | ||||
| 2021-03-31 | $136.00K 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |